Stages of the cannabis plant
Today, we will gain understanding about the photoperiod in a cannabis plant’s life cycle as they grow and develop. As we know, cannabis plant is annual and, in order to guarantee its proper growth outdoors,…
Iberian Peninsula express shipping
0€ Orders over 60€
*6€ orders under 59€
East, West, South Europe express shipping
0€ Orders over 150€
*18€ orders under 149€
North Europe express shipping
0€ Orders over 160€
*20€ orders under 159€
Ireland, Norway, UK normal shipping
0€ Orders over 60€
*6€ orders under 59€
Rest of the world normal shipping
0€ Orders over 180€
*25€ orders under 179€
Shipping costs can be confirmed in your shopping cart.
For additional shipping methods, please reach out through info@kannabia.com.
*Website protected by SSL.
**Not available in all regions.
*Your coupon will be sent via email.
*Should you have any question, comment or feedback, please do not hesitate to contact us.
2016 has seen a radical change in the European wide process to legalise cannabis and more and more countries are standing up to be counted. We at Kannabia have played our part and are happy to be included among those who have taken these latest steps (whether big or small) especially in reference to the 2016 regulation which specifies recreational theraputic use.
Sixteen American states have regulated cannabis with clear medicinal objectives in mind. This year, states such as California, Massachussets, Nevada and Maine have passed legislation to permit the use of cannabis as a recreational drug.
In Europe as a whole, countries such as France, The UK, Ireland, Macedonia and Portugal have all opened the debate and taken steps to normalise and vindicate the use of cannabis as both a theraputical and recreational drug.
Latin America is leading by example
The president of Mexico, Enrique Peña Nieto, has proposed the limited legalisation of the drug (controlled cultivation etc) as a counter measure to widespread crime. This proposal was delivered at a Federal and Senate level and has tremendous potential. Argentina and Colombia are debating the benefits of regularisation although this process looks as if it may be a drawn out one. In the case of Uruguay, although the use of cannabis as a theraputic drug remains an open and positive debate, the process has somewhat stagnated due to the question of selling the drug in pharmacies. This situation neither helps the existing market nor the development of a new one.
All told, we at Kannibia are very happy with the steps taken and the ground covered throughout 2016 and we will move forward with the same momentum in 2017. Keep the ball rolling!